Unlocking Allogeneic Cell Therapy: Exploring Durable Approaches

Autologous cell therapies for cancer, while effective, are hampered by being complex, expensive, and difficult to scale. The future lies in allogeneic approaches, which use a single donor to treat multiple patients, making them more scalable and cost-effective. However, their main challenge is durability: the patient's immune system often clears the transplanted cells, leading to inflammation.

In this webinar, Dr. Ruby Tsai, Chief Scientific Officer of Applied StemCell, details how allogeneic developers are overcoming these durability hurdles. She examines successful methods across the entire pipeline—from approved therapies and clinical trials to pre-IND approaches. Discover how genome engineering and iPSCs are key to finally achieving scalable allogeneic cell therapies.

Key Takeaways:

• Explore strategies for achieving durable allogeneic cell therapies.
• Review methods currently used in approved, clinical-stage, and developing treatments.
• Understand the role of engineered iPSC lines in creating scalable allogeneic cell therapies.